The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 14, 1998

Filed:

Jun. 07, 1995
Applicant:
Inventors:

Michael A Palladino, Olivenhain, CA (US);

Bruce A Lee, San Diego, CA (US);

William D Huse, San Diego, CA (US);

Judith A Varner, Encinitas, CA (US);

Assignee:

IXSYS, Incorporated, San Diego, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K / ; C07K / ;
U.S. Cl.
CPC ...
514-9 ; 530317 ; 530329 ; 514 11 ; 514 17 ;
Abstract

The present invention includes non-RGD cyclic peptides that inhibit the function of the integrin receptor, .alpha..sub.v .beta..sub.3. The inventive peptides are between five to about thirty amino acids in length and include the sequence (SEQ ID NO:8), Arg-Cys-Asp-Gly-X.sub.i where X.sub.i is any amino acid, and a five-membered cyclic portion. These non-RGD peptides display surprisingly potent antagonist activity despite the lack of the consensus binding sequence Arg-Gly-Asp, and present opportunities for selective targeting to the .alpha..sub.v .beta..sub.3 receptor. Pharmaceutical compositions and methods of use are also disclosed. The therapeutic uses for the inventive peptides include treating diseases involving .alpha..sub.v .beta..sub.3 receptors such as cancer, osteoporosis, restenosis, and angiogenic-based diseases.


Find Patent Forward Citations

Loading…